DNLI Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
3.6M
0
0
0
0
Cost of Revenue
93.0K
0
0
0
0
Gross Profit
3.5M
0
0
0
0
Operating Expenses
134.1M
-2.4%
137.4M
-0.0%
137.4M
-0.1%
137.4M
+1.8%
135.0M
R&D
97.0M
-6.6%
103.8M
+6.1%
97.9M
-4.0%
102.0M
-0.7%
102.7M
SG&A
36.3M
+8.3%
33.5M
-15.1%
39.5M
+11.2%
35.5M
+10.0%
32.3M
Operating Income
-130541000
+5.0%
-137357000
+0.0%
-137365000
+0.1%
-137434000
-1.8%
-134963000
EBITDA
-126972000
+5.6%
-134512000
-0.0%
-134499000
-0.0%
-134487000
-1.9%
-131918000
Net Income
-127553000
+0.7%
-128447000
+0.1%
-128549000
-1.3%
-126902000
-2.2%
-124119000
EPS (Basic)
$-0.68
+1.4%
$-0.69
+5.5%
$-0.73
+1.4%
$-0.74
-2.8%
$-0.72
EPS (Diluted)
$-0.68
+1.4%
$-0.69
+5.5%
$-0.73
+1.4%
$-0.74
-2.8%
$-0.72
Shares (Diluted)
187.3M
+0.4%
186.6M
+6.3%
175.5M
+1.8%
172.4M
+0.6%
171.4M
Denali Therapeutics (DNLI) โ€” Financials